Form 1 NCTN Survey

Generic Clearance for NIH Citizen Science and Crowdsourcing Projects (OD)

SurveyMonkey Print Preview - NCTN Survey 6-2-22

NCTN Performance Measurement Survey (NCI)

OMB: 0925-0766

Document [pdf]
Download: pdf | pdf
INc1iiAW
Trials Network

a National Cancer Institute program

Introduction
The National Cancer Institute (NCI) would like to know about your experiences with the National
Clinical Trials Network (NCTN).
Your input will help NCI assess and refine the NCTN processes and identify areas for
improvement.
The survey will ask questions about NCTN structure, processes, and goals. It should take
approximately 10 minutes to complete.
Your responses will be kept private to the extent of the law and will be reported in the aggregate.
Your participation in this survey and your responses will have no bearing on your NCTN
participation or your future interactions with NCI. No personally identifying information will be
collected. We truly appreciate your honest input about your experiences with the NCTN.
Thank you for your assistance!
To continue and begin the survey, click the "Next" button below.
0MB Public Reporting Burden Statement
0MB No.: 0925-0766
Expiration Date: 4/30/2023
Public reporting burden for this collection of information is estimated to average 10 minutes per
response, including the time for reviewing instructions, searching existing data sources, gathering
and maintaining the data needed, and completing and reviewing the collection of information. An
agency may not conduct or sponsor, and a person is not required to respond to, a collection
of information unless it displays a currently valid 0MB control number. Send comments
regarding this burden estimate or any other aspect of this collection of information, including
suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive,
MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0766). Do not return the completed form
to this address.

4. What disease area best describes your area of medical expertise? (select one)

0 Brain malignancies
0 Breast cancer
0 Gastrointestinal cancers
0 Genitourinary cancers
0 Gynecologic cancers
0 Head and neck cancers
0 Hematologic cancers (adult)
0 Hematologic cancers (pediatric)
0 Pediatric solid tumors
0 Thoracic malignancies
0 Not applicable
0 Other (please specify)

8. What changes to the NCTN program do you think would significantly help improve
enrollment and/or retention of diverse patient populations?

9. For any other items above that you thought needed improvement, what improvements
or changes would you like to see?

11. Overall, how satisfied are you with the following programs within the NCTN?
Unsatisfactory Needs
Significant
Improvement

Does Not Meet
Expectations Needs Some
Improvement

Meets
Expectations

Exceeds
Expectations

N/A

Imaging and Radiation
Oncology Core (IROC)

0

0

0

0

0

NCTN Biospecimen Banks

0

0

0

0

0

Lead Academic
Participating Sites (LAPS)

0

0

0

0

0

For any items above that you thought needed improvement, what improvements or changes would
you like to see?

12. Overall, how satisfied are you with the following aspects of the NCTN menu of trials?

Unsatisfactory Needs
Significant
Improvement

Does Not Meet
Expectations Needs Some
Improvement

Meets
Expectations

Exceeds
Expectations

N/A

Number of NCTN trials
available

0

0

0

0

0

Portfolio of NCTN trials
available

0

0

0

0

0

Number of NCTN trials for
adolescents and young
adults (AYAs) available

0

0

0

0

0

For any items above that you thought needed improvement, what improvements or changes would
you like to see?

INc1iiAW
Trials Network

a National Cancer Institute program

Use of New Processes for the Conduct of NCTN Clinical Trials
NCI CTEP provided guidance and modifications for the conduct of NCTN clinical trials during the
COVID-79 pandemic. Some of these modifications will continue as permanent new processes. We
would like to know whether your site will use these new processes, and if so, how useful you think
the new processes are.

13. For each of the following new processes, does your site plan to continue to use the
new process? If so, how useful do you think the new process is for the conduct of NCTN
trials at your site?
Yes. My site

plans to
No. My site
continue to use
does not plan to
this process.
continue to use It is Not at All
this process.
Useful

Shipping CTEP IND oral
agents from your site to
patients

Yes. My site

plans to
continue to use
this process.
It is Somewhat

Yes. My site

Useful

plans to
continue to use
this process.
It is Very Useful

Not Applicable
(N/A) or Don't
Know

0

0

0

0

0

0
0

0
0

0
0

0
0

0
0

Telehealth for NCTN study
visits

0

0

0

0

0

Working with local
healthcare providers to
perform certain NCTN
study activities

0

0

0

0

0

Allowing Advanced Practice
Providers to authorize
study agent orders on
NCTN trials

0

0

0

0

0

Remote consent
Remote auditing

What changes to the NCTN program do you think would significantly help the efficient and
effective conduct of NCTN trials at your site?

INc1iiAW
Trials Network

a National Cancer Institute program

Efforts to Broaden Eligibility Criteria in NCTN Trials
NCI CTEP is working to broaden eligibility in NCTN trials (see
https://ctep.cancer.gov/protocolDevelopment/docs/CTEP Broadened Eligibility Criteria Guidance.
_pd£ for more information). We would like to know which of the categories of broadened eligibility
criteria you think have the potential to have the greatest impact in NCTN trials.

14. Which of the following categories of broadened eligibility criteria do you think will
have the greatest impact?
Not at All Useful

Somewhat Useful

Very Useful

Not Applicable (N/A)
or Don't Know

Treated/stable brain
metastases

0

0

0

0

New/progressive brain
metastases

0

0

0

0

HIV, HBV, and HCV
infection

0

0

0

0

Prior/concurrent
malignancies

0

0

0

0

Organ function: cardiac,
liver, and kidney

0

0

0

0

0
0
0

0
0
0

0
0
0

0
0
0

Laboratory reference
ranges and test intervals

0

0

0

0

Performance status

0

0

0

0

Psychiatric illness/social
situations

0

0

0

0

Washout periods
Concomitant medications
Prior therapies

What, if any, additional improvements or changes would you like to see in the broadening eligibility
efforts in the NCTN?

INc1iiAW
Trials Network

a National Cancer Institute program

Final Thoughts
15. What, if any, improvements or changes would you like to see in the NCTN that you did
not describe previously?

Thank you for providing your feedback about the NCTN program!
We appreciate your help.
Please hit the "Submit" button below to submit your answers.
If you would like to provide any additional information, please email us at
[email protected]


File Typeapplication/pdf
File Modified2022-06-15
File Created2022-06-01

© 2024 OMB.report | Privacy Policy